AU2017208123B2 - Methods and formulations for treatment of and/or protection against acute liver failure and other hepatotoxic conditions - Google Patents

Methods and formulations for treatment of and/or protection against acute liver failure and other hepatotoxic conditions Download PDF

Info

Publication number
AU2017208123B2
AU2017208123B2 AU2017208123A AU2017208123A AU2017208123B2 AU 2017208123 B2 AU2017208123 B2 AU 2017208123B2 AU 2017208123 A AU2017208123 A AU 2017208123A AU 2017208123 A AU2017208123 A AU 2017208123A AU 2017208123 B2 AU2017208123 B2 AU 2017208123B2
Authority
AU
Australia
Prior art keywords
active agent
manganese
individual
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017208123A
Other languages
English (en)
Other versions
AU2017208123A1 (en
Inventor
Dennis Henriksen
Sven JACOBSSON
Jacques Nasstrom
James Van Alstine
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Egetis Therapeutics AB
Original Assignee
Egetis Therapeutics AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Egetis Therapeutics AB filed Critical Egetis Therapeutics AB
Publication of AU2017208123A1 publication Critical patent/AU2017208123A1/en
Assigned to EGETIS THERAPEUTICS AB reassignment EGETIS THERAPEUTICS AB Amend patent request/document other than specification (104) Assignors: PLEDPHARMA AB
Application granted granted Critical
Publication of AU2017208123B2 publication Critical patent/AU2017208123B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dispersion Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2017208123A 2016-01-11 2017-01-10 Methods and formulations for treatment of and/or protection against acute liver failure and other hepatotoxic conditions Active AU2017208123B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662277232P 2016-01-11 2016-01-11
US62/277,232 2016-01-11
US201662361605P 2016-07-13 2016-07-13
US62/361,605 2016-07-13
PCT/IB2017/050115 WO2017122120A1 (en) 2016-01-11 2017-01-10 Methods and formulations for treatment of and/or protection against acute liver failure and other hepatotoxic conditions

Publications (2)

Publication Number Publication Date
AU2017208123A1 AU2017208123A1 (en) 2018-07-19
AU2017208123B2 true AU2017208123B2 (en) 2022-04-21

Family

ID=57909814

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017208123A Active AU2017208123B2 (en) 2016-01-11 2017-01-10 Methods and formulations for treatment of and/or protection against acute liver failure and other hepatotoxic conditions

Country Status (8)

Country Link
US (2) US11260060B2 (enExample)
EP (2) EP3842040B1 (enExample)
JP (2) JP7311267B2 (enExample)
CN (1) CN108601757A (enExample)
AU (1) AU2017208123B2 (enExample)
CA (1) CA3010915C (enExample)
RU (1) RU2018128793A (enExample)
WO (1) WO2017122120A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017122120A1 (en) * 2016-01-11 2017-07-20 Pledpharma Ab Methods and formulations for treatment of and/or protection against acute liver failure and other hepatotoxic conditions
WO2019046646A1 (en) 2017-08-30 2019-03-07 Whole Biome Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF MICROBIOMA ASSOCIATED DISORDERS
RU2693677C1 (ru) * 2018-10-15 2019-07-03 Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" (ГБУЗ МО МОНИКИ им. М.Ф. Владимирского) Способ гемокоррекции при лечении печеночной недостаточности
EP3973047A4 (en) * 2019-05-21 2023-01-11 Pendulum Therapeutics, Inc. METHODS AND COMPOSITIONS FOR TREATING HEPATIC DISORDERS
WO2022269026A1 (en) 2021-06-25 2022-12-29 Forschungsgesellschaft Für Arbeitsphysiologie Und Arbeitsschutz E. V. Treating acetaminophen overdose
WO2024095178A1 (en) 2022-11-01 2024-05-10 Janssen Pharmaceutica Nv Thrombopoietin mimetic for use in the treatment of acute liver failure

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020142991A1 (en) * 2001-03-30 2002-10-03 Herzenberg Leonore A. N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity
WO2002087579A1 (fr) * 2001-04-26 2002-11-07 Universite Rene Descartes (Paris V) Utilisation du mangafodipir dans le traitement des effets d'un stress oxydatif
US20080139654A1 (en) * 2006-12-09 2008-06-12 Eric Mott Soderling Acetaminophen compositions having minimized side effects including reduced hepatotoxicity

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050070607A1 (en) 2003-08-19 2005-03-31 James Andrus N-acetylcysteine compositions and methods for the treatment and prevention of cysteine/glutathione deficiency in diseases and conditions
KR20080028357A (ko) 2005-04-21 2008-03-31 글렌 에이. 골드스타인 산화성 스트레스에 관련된 질병 및 증상 치료용ｎ-아세틸시스테인 아미드(ｎａｃ 아미드)
ZA200902203B (en) 2006-10-23 2010-08-25 Mental Health Res Inst Of Vict Combination therapy
JP5868852B2 (ja) * 2009-07-06 2016-02-24 プレッドファルマ・アーベー マンガン錯体化合物と非マンガン錯体形態の同化合物の組み合わせを用いる医薬組成物及び治療方法
MX2014008247A (es) * 2012-01-05 2015-03-09 Pledpharma Ab Calmangafodipir, una nueva entidad quimica, y otros complejos de metal mezclados, metodos de preparacion, composiciones y metodos de tratamiento.
US20140178358A1 (en) * 2012-12-21 2014-06-26 The United States of America as represented by the Secretary of Department of Health and Human Servi Means and Methods to Diagnose Liver Toxicity using Putrescine as Biomarker
WO2017122120A1 (en) 2016-01-11 2017-07-20 Pledpharma Ab Methods and formulations for treatment of and/or protection against acute liver failure and other hepatotoxic conditions

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020142991A1 (en) * 2001-03-30 2002-10-03 Herzenberg Leonore A. N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity
WO2002087579A1 (fr) * 2001-04-26 2002-11-07 Universite Rene Descartes (Paris V) Utilisation du mangafodipir dans le traitement des effets d'un stress oxydatif
US20080139654A1 (en) * 2006-12-09 2008-06-12 Eric Mott Soderling Acetaminophen compositions having minimized side effects including reduced hepatotoxicity

Also Published As

Publication number Publication date
RU2018128793A3 (enExample) 2020-05-25
JP2019501226A (ja) 2019-01-17
JP7374163B2 (ja) 2023-11-06
AU2017208123A1 (en) 2018-07-19
WO2017122120A1 (en) 2017-07-20
EP3842040B1 (en) 2022-03-09
RU2018128793A (ru) 2020-02-13
CA3010915C (en) 2024-06-04
JP2022019973A (ja) 2022-01-27
EP3402475B1 (en) 2021-10-20
JP7311267B2 (ja) 2023-07-19
EP3842040A1 (en) 2021-06-30
EP3402475A1 (en) 2018-11-21
US11260060B2 (en) 2022-03-01
US20220133739A1 (en) 2022-05-05
CN108601757A (zh) 2018-09-28
CA3010915A1 (en) 2017-07-20
US12303516B2 (en) 2025-05-20
US20190015424A1 (en) 2019-01-17

Similar Documents

Publication Publication Date Title
US12303516B2 (en) Methods and formulations for treatment of and/or protection against acute liver failure and other hepatotoxic conditions
Fishbane N-acetylcysteine in the prevention of contrast-induced nephropathy
McGregor et al. Rationale and impact of vitamin C in clinical nutrition
Fishbane et al. N-acetylcysteine in the prevention of radiocontrast-induced nephropathy
Crabtree et al. Ratio of 5, 6, 7, 8-tetrahydrobiopterin to 7, 8-dihydrobiopterin in endothelial cells determines glucose-elicited changes in NO vs. superoxide production by eNOS
US20050070607A1 (en) N-acetylcysteine compositions and methods for the treatment and prevention of cysteine/glutathione deficiency in diseases and conditions
Morocco Cyanides
JP6591995B2 (ja) ドーパデカルボキシラーゼ阻害剤組成物
CN103038356A (zh) 乙酰半胱氨酸组合物及其使用方法
Heard et al. Acetylcysteine therapy for acetaminophen poisoning
WO2003063780A2 (en) Therapeutic composition for treatment of cancer by arginine depletion
JP2019501226A5 (enExample)
Aleksa et al. Young age and the risk for ifosfamide-induced nephrotoxicity: a critical review of two opposing studies
Shalansky et al. N‐acetylcysteine for Prevention of Radiographic Contrast Material–Induced Nephropathy: Is the Intravenous Route Best?
Kociancic et al. Acetaminophen intoxication and length of treatment: how long is long enough?
HK40056482B (en) Methods and formulations for treatment of and/or protection against acute liver failure and other hepatotoxic conditions
HK40056482A (en) Methods and formulations for treatment of and/or protection against acute liver failure and other hepatotoxic conditions
Rahimi et al. Novel ammonia-lowering agents for hepatic encephalopathy
Smith Drugs and pharmaceuticals: management of intoxication and antidotes
HK1260784B (en) Methods and formulations for treatment of and/or protection against acute liver failure and other hepatotoxic conditions
Patel et al. Amlodipine overdose
CN104619316B (zh) 用于降低n-氧化三甲胺水平的药物组合物
JP2004526792A (ja) 酸化的侵襲効果を治療するためのマンガフォジピルの使用
Tan et al. Acute kidney injury and iron metabolism: A narrative review focusing on pathophysiology and therapy
Dallatu et al. Risk of endothelial dysfunction in streptozotocin-induced diabetic Sprague-Dawley rats: Nitric oxide in focus

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: EGETIS THERAPEUTICS AB

Free format text: FORMER NAME(S): PLEDPHARMA AB

FGA Letters patent sealed or granted (standard patent)